证券代码：301371 证券简称：敷尔佳 公告编号：2025-020 哈尔滨敷尔佳科技股份有限公司 关于第三类医疗器械产品完成临床试验备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）在研产品"重 组Ⅲ型人源化胶原蛋白贴敷料"通过该产品临床试验所有中心伦理委员会的伦理 审查，并在黑龙江省药品监督管理局完成分中心盘锦辽油宝石花医院的医疗器械 临床试验备案，公司在研产品"重组Ⅲ型人源化胶原蛋白贴敷料"已经可以开展 临床试验。具体情况公告如下： 一、基本情况 （一）临床试验备案项目一 1、申办者：哈尔滨敷尔佳科技股份有限公司 2、申办地址：哈尔滨市松北区美谷路 500 号 3、试验名称：评价重组Ⅲ型人源化胶原蛋白贴敷料用于激光、光子术后创 面修复辅助治疗的有效性和安全性 4、试验目的：通过与广州创尔生物技术股份有限公司生产的胶原贴敷料对 比，评价公司研制的重组Ⅲ型人源化胶原蛋白贴敷料（MRC-W-T）用于激光、光 子术后面部皮肤创面修复辅助治疗的有效性、安全性 5、试验用医疗器械名称：重组Ⅲ型人源化胶原 ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 2.02 billion yuan in 2024, representing a year-on-year growth of 4.3%, while the net profit attributable to shareholders was 660 million yuan, down 11.8% year-on-year. In Q1 2025, the revenue was 300 million yuan, a decline of 26.4% year-on-year, and the net profit attributable to shareholders was 90 million yuan, down 39.8% year-on-year [2][4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.02 billion yuan, with a net profit of 660 million yuan. The revenue growth was primarily driven by the cosmetics segment, which saw a 7.5% increase year-on-year, while the medical device segment remained stable with a 0.3% increase [9] - For Q1 2025, the company experienced a significant revenue drop of 26.4% year-on-year, attributed to proactive channel and product optimization efforts [9] Product and Channel Strategy - The company has successfully expanded its product offerings, with several products achieving annual sales exceeding 100 million yuan. The online sales channel has also seen substantial growth, with a 20% increase in revenue [9] - The company is focusing on enhancing its brand presence in e-commerce platforms, which has contributed to a significant increase in online sales [9] Profitability Metrics - The overall gross margin for 2024 was 82%, with a slight decrease of 0.5 percentage points. The net profit margin decreased by 6 percentage points to 32.8%, primarily due to an increase in sales expense ratio [9] - In Q1 2025, the net profit margin further declined by 6.7 percentage points, influenced by a rise in sales expenses and adjustments in product pricing [9] Future Outlook - The company is expected to stabilize its revenue and profitability through the formation of repeat purchases of core products and the gradual establishment of e-commerce strategies. EPS forecasts for 2025, 2026, and 2027 are projected to be 1.74 yuan, 1.89 yuan, and 2.05 yuan respectively [9]

关于哈尔滨敷尔佳科技股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：敷尔佳 | | --- | --- | | 保荐代表人姓名：鄢凯红 | 联系电话：010-6083-8304 | | 保荐代表人姓名：范新亮 | 联系电话：010-6083-4190 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | | 是，根据敷尔佳2024年度内控自我评价报告、 | | （2）公司是否有效执行相关规章制度 | 2024年度内部控制审计报告，发行人有效执行 | | | 了相关规章制度。 | | 3.募集资金监督情况 | | | | 保荐人每月查询公司募集资金 ...

哈尔滨敷尔佳科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 14 日召开的 2024 年年度股东会审议通过，现将权 益分派事宜公告如下： 一、股东会审议通过权益分派方案的情况 1、公司于 2025 年 5 月 14 日召开 2024 年年度股东会，审议通过了《关于 2024 年度利润分配预案的议案》，同意公司以总股本 400,080,000 股为基数，向全体在 册股东按每 10 股派发现金股利 10 元人民币（含税），合计派发现金股利 400,080,000.00 元（含税），以资本公积向全体股东每 10 股转增 3 股，共计转增 120,024,000 股，转增后公司总股本为 520,104,000 股，剩余未分配利润结转以后 年度分配，本年度不送红股。本次预案经股东会审议通过之日至利润分配方案实施 日，公司股本如发生变动，公司将按照分配比例不变的原则对分配总额进行相应调 整。 2、本次权益 ...

北京市中伦（深圳）律师事务所 关于哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年五月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing o • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（深圳）律师事务所 关于哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会的 法律意见书 致：哈尔滨敷尔佳科技股份有限公司 北京市中伦（深圳）律师事务所（下称"本所"）接受哈尔滨敷尔佳科技股 份有限公司（下称"公司"）的委托，指派律师出席公司 2024 年年度股东会（下 称"本次股东会"），并根据《中华人民共和 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2025-018 哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 3、召开方式：现场表决与网络投票相结合的方式。 4、召集人：公司董事会 5、主持人：公司董事长张立国先生 6、会议召开的合法、合规性：本次股东会的召集、召开及表决方式符合《中华 人民共和国公司法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规 则》等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 1 （一）会议召开情况 1、召开时间 （1）现场会议召开时间：2025 年 5 月 14 日（星期三）下午 14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 14 日的交易时间，即上午 9：15-9：25、9:30-11:30 和下午 13:00-15:00； 通过深圳证券交易所互联网投票 ...

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. is demonstrating resilience and potential in the competitive medical beauty skincare market, focusing on precise consumer demand and diversified market expansion [2] Group 1: Market Performance - In 2024, Fulejia achieved operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32% [2] - Online sales reached 1.108 billion yuan in 2024, growing by 20.03% year-on-year, with strong performance during promotional events [3] Group 2: R&D and Innovation - R&D expenses increased by 6.04% in 2024, with the number of R&D personnel growing by 114.81% [3] - The completion of a self-owned production base and the establishment of a Shanghai R&D center in 2024 signify a strengthened R&D capability [3] Group 3: Shareholder Returns and Strategic Adjustments - Fulejia announced its first dividend in May 2024, with plans for another before the Spring Festival in early 2025, aiming to enhance stock liquidity [4] - The company is optimizing sales channel structures and strengthening product pricing management for long-term sustainable development [4][5] Group 4: Competitive Advantage - The acquisition of Harbin Beixing Pharmaceutical Co., Ltd. has provided Fulejia with independent production capabilities, laying a solid foundation for long-term growth [5] - The company aims to leverage its comprehensive competitive advantages in R&D, products, branding, resources, and market to enhance its position in the medical beauty skincare sector [5]

1、访谈公司董事会秘书、财务负责人，了解公司治理和内部控制情况、2024 年度公司整体经营情况、信息披露情况、关联交易及其他关联方资金往来情况、 重大对外投资情况、募集资金使用情况等； 2、察看上市公司主要生产经营场所； 3、取得公司现行治理规则和内控制度等规则，核查公司章程、股东大会、 董事会、监事会议事规则等公司基本制度，查阅了股东大会、董事会及监事会决 议及记录； 中信证券股份有限公司 关于哈尔滨敷尔佳科技股份有限公司 2024 年度持续督导工作现场检查报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：敷尔佳 | | | | | --- | --- | --- | --- | --- | | 保荐代表人姓名：鄢凯红 | 联系电话：010-6083 8304 | | | | | 保荐代表人姓名：范新亮 | 联系电话：010-6083 4190 | | | | | 现场检查人员姓名：鄢凯红、姜逸茵 | | | | | | 现场检查对应期间：2024 年 1 月 1 日-2024 | 年 12 月 31 日 | | | | | 现场检查时间：2025 年 4 月 14 日-2025 年 4 | ...

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. (301371.SZ) has delivered a stable and impressive 2024 annual report amidst a challenging consumer environment in the cosmetics industry, showcasing systematic optimization in product strategy, R&D layout, and sales structure [1] Group 1: Business Performance - In 2024, the company achieved operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32%, with medical device revenue at 853 million yuan, accounting for 42.28%, and cosmetic revenue at 1.164 billion yuan, growing by 7.49% and making up 57.72% [1] - The dual-driven strategy of "medical devices + functional skincare" is highlighted, with a balanced development pattern between the two sectors [1] Group 2: Product Development - The company launched over ten new functional skincare products, including "lactic acid oil-control mask" and "blue copper peptide soothing series," addressing various skincare needs such as whitening and anti-wrinkle [2] - The average price of self-developed skincare products in 2024 is approximately 34.82 yuan, aligning with the trend of consumer upgrading while emphasizing scientific ingredients and efficacy [2] Group 3: R&D and Innovation - R&D investment reached 34.82 million yuan in 2024, a year-on-year increase of 6.04%, with the Shanghai R&D center officially operational, enhancing the company's R&D capabilities [2] - The company has obtained 29 patent authorizations, including 7 invention patents, and is advancing clinical trials for III-class medical devices, indicating a strategic focus on the medical aesthetics sector [3] Group 4: Market Strategy - The company employs a "hit products + long-term iteration" strategy, with several products achieving over 100 million yuan in sales, such as "medical sodium hyaluronate repair patch" and "niacinamide whitening mask," maintaining stable growth [4] - The establishment of a sensory evaluation laboratory and collaboration with third-party research institutions for efficacy validation enhances brand credibility and consumer experience [4] Group 5: Long-term Vision - The company emphasizes a long-term development path centered on products and supported by technology, avoiding short-term explosive growth in favor of sustainable value creation [5] - As the demand for effective skincare becomes more scientific, segmented, and personalized, the company is evolving from a "hit product" model to a "brand cluster + technology platform" approach, indicating potential for greater growth [6]

Core Viewpoint - The article highlights how Fulejia, known as the "first stock of medical dressings," is redefining the domestic skincare market by shifting from "ingredient competition" to "mechanism innovation," leveraging scientific advancements to enhance product efficacy and establish a competitive edge in the increasingly saturated beauty industry [1][3]. Group 1: Industry Trends - The domestic beauty industry is experiencing intense competition, with brands previously relying on popular ingredients and marketing strategies to attract consumers [1]. - The trend of "ingredient stacking" has led to market homogenization, failing to address complex skin issues and lacking long-term competitiveness [1]. Group 2: Company Innovations - Fulejia has adopted supramolecular technology as a core competitive advantage, allowing for the design and recombination of different functional molecules into new supramolecular structures, enhancing product efficacy [2]. - The company has developed several innovative raw materials using supramolecular technology, such as supramolecular white pool flower seed oil and supramolecular grape seed oil, which improve skin nourishment and penetration efficiency [2]. Group 3: Research and Development - Fulejia actively collaborates with various universities and research institutions to explore cutting-edge fields, ensuring that technological innovations align with market demands [3]. - The company emphasizes a research and development system that integrates external scientific resources, focusing on the physiological mechanisms of skin rather than merely competing on ingredient concentrations [3].